Premium
Bromfenac – a new standard in NSAID efficacy
Author(s) -
FINDL O
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.494.x
Subject(s) - medicine , tolerability , macular edema , miosis , cataract surgery , clinical trial , ophthalmology , anesthesia , adverse effect , pharmacology , visual acuity
NSAIDs are increasingly used in ophthalmology to reduce surgically induced miosis and inflammation, and in the prevention and therapy of cystoid macular edema (CME). For the treatment of postoperative inflammation following cataract surgery, bromfenac, a new NSAID, has been studied in several clinical trials in recent years. During our discourse, we will elaborate on the following: ‐ Bromfenac’s mechanism of action ‐ Recent clinical data of pivotal/other bromfenac trials ‐ Bromfenac’s safety, tolerability and use in combination with corticosteroids